Skip to Content

ResMed Inc

RMD: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$622.00JscqclGdgrkwlgs

ResMed's Moat Is Underpinned by Switching Costs and Intangible Brand Assets

Business Strategy and Outlook

ResMed is taking a “smart devices” and Big Data approach to further entrench itself as one of the two leading players in the global obstructive sleep apnea, or OSA, market. With cloud-connected devices, physicians can monitor patient compliance and encourage continued use. Higher adherence supports both reimbursement rates from payers and the resupply of masks and accessories. ResMed also plays a key role in producing clinical data that demonstrates treatment can minimize related risks such as hypertension, stroke, heart attack and Alzheimer’s disease. Through its own testing devices and education, ResMed seeks more widespread diagnosis and treatment of OSA.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of RMD so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center